12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Brivanib regulatory update

The European Commission granted Orphan Drug designation for Bristol-Myers' brivanib to treat hepatocellular carcinoma (HCC). The prodrug...

Read the full 62 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >